Denali Therapeutics
DNLI
213 hedge funds and large institutions have $3.8B invested in Denali Therapeutics in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 86 increasing their positions, 62 reducing their positions, and 27 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 62
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
0.08% more ownership
Funds ownership: 69.74% → 69.82% (+0.08%)
0% less funds holding
Funds holding: 214 → 213 (-1)
11% less capital invested
Capital invested by funds: $4.28B → $3.8B (-$480M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
77% less call options, than puts
Call options by funds: $2.6M | Put options by funds: $11.3M
Top Buyers
| 1 |
Bank of New York Mellon
New York
|
+$26.3M |
| 2 |
BlackRock
New York
|
+$26.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$18.8M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$15.9M |
Top Sellers
| 1 |
PCM
Pathway Capital Management
Irvine,
California
|
-$51.1M |
| 2 |
Goldman Sachs
New York
|
-$30.6M |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$20M |
| 4 |
CC
Casdin Capital
New York
|
-$9.48M |
| 5 |
Two Sigma Advisers
New York
|
-$7.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJFSA
226
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$215K | -4,252 | Closed |
|
|
PRC
227
Pearl River Capital
Niles,
Michigan
| – | -$211K | -4,175 | Closed |
|
|
BCB
228
Brian C. Broderick
| – | -$202K | -4,000 | Closed |
|
|
MAM
229
Meeder Asset Management
Dublin,
Ohio
| – | -$186K | -3,669 | Closed |
|
230
Lazard Asset Management
New York
| – | -$59K | -1,186 | Closed |
|
|
RE
231
RBC Europe
London,
United Kingdom
| – | -$22.7K | -450 | Closed |
|
|
SBL
232
Sargent Bickham Lagudis
Boulder,
Colorado
| – | -$8K | -165 | Closed |
|
|
APWA
233
Atlas Private Wealth Advisors
Matawan,
New Jersey
| – | -$1K | -15 | Closed |
|
|
BIA
234
Bell Investment Advisors
Oakland,
California
| – | -$616 | -13 | -54% |
|
|
EI
235
Ellevest Inc
New York
| – | -$190 | -4 | -27% |
|
236
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$95 | +2 | New |
|
|
SC
237
Schubert & Co
Mckinney,
Texas
| – | +$284 | +6 | New |
|
DNLI Hedge Fund Activity: Q4 2021 in Review
213 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2021, worth a combined $3.8B — down 11% from $4.28B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DNLI positions and 27 closed out — a net gain of 2 holders — while 86 added to existing stakes and 62 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $26.3M. The largest seller was Pathway Capital Management, exiting entirely with an estimated $51.1M sold.
- 213 institutional investors held Denali Therapeutics (DNLI) as of Q4 2021, down from 214 in Q3 2021.
- Funds reported $3.8B of Denali Therapeutics stock for Q4 2021, down 11% quarter-over-quarter.
- 29 funds opened new Denali Therapeutics positions in Q4 2021 and 27 closed out, a net change of +2 holders.
- The largest Denali Therapeutics buyer in Q4 2021 was Bank of New York Mellon, an estimated $26.3M added.
- The largest Denali Therapeutics seller in Q4 2021 was Pathway Capital Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q4 2021.